TRiCares Raises $50M in Series D Funding for Tricuspid Heart Valve System

TRiCares raises $50M in Series D Funding

TRiCares (Linkedin), a leading medical device company based in the United States, recently secured $50 million in Series D funding. Their focus on tricuspid regurgitation treatment and the development of their transfemoral tricuspid heart valve replacement system, Topaz, positions them as a key player in the field of minimally invasive heart valve treatments.

Funding Amount: $50 million

Industry: Medical Equipment Manufacturing

Employee Count: 11-50

CEO: Ahmed Elmouelhi (CEO Linkedin)

What TRiCares needs to buy: TRiCares is seeking partnerships with research institutions, medical centers, and manufacturers to support their clinical trials, manufacturing, and distribution efforts. Additionally, regulatory compliance services will be crucial in navigating the complex landscape of medical device approvals and certifications.